CNS Drugs

, Volume 31, Issue 10, pp 857–866 | Cite as

Do Pharmaceuticals Improve Driving in Individuals with ADHD? A Review of the Literature and Evidence for Clinical Practice

  • Craig B. H. Surman
  • Ronna Fried
  • Lauren Rhodewalt
  • Heidi Boland
Review Article
  • 182 Downloads

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is defined as a disorder of impaired attention and/or behavioral control. Studies suggest that the condition can dispose individuals to a higher risk of automobile accidents. ADHD symptoms respond to pharmacotherapy in a majority of uncomplicated cases. Evidence on how pharmacotherapies for ADHD impact driving behavior or outcomes could allow clinicians to support on-road safety rationally. We therefore undertook a review to identify the evidence base to date indicating positive or negative effects of pharmacotherapies on driving behavior in individuals with ADHD. Further, we evaluated the level of evidence for these effects, their specificity to ADHD, and how they may inform clinical care. We identified studies involving pharmacotherapy for ADHD that evaluated driving-related activities or outcomes. We then categorized these studies by the mode of measurement used and by the ADHD specificity of the driving behaviors measured. Finally, we extracted themes of interest to clinical practice in pharmacologic intervention. In total, 14 studies, involving 2–61 subjects diagnosed with ADHD, looked at computer-measured, observer-measured, or self-reported driving behavior correlates of pharmacotherapy during simulation or on-road driving. Of these studies, 13 involved psychostimulant agents and two used atomoxetine. All but three investigations (one of methylphenidate, one of mixed amphetamine salts, and one of atomoxetine) found favorable changes in measures such as steering and braking behaviors or reaction to unexpected events. One study found adverse effects on driving at hour 17 following mixed amphetamine salt administration. Four studies compared two pharmacotherapies, and each found differences in measured driving behavior between the therapies. One study explored impact on ADHD-specific driving impairments, and the same study was the only one to explore correlation of clinical measures (ADHD symptoms and self-reported driving behavior) with medication-associated changes—finding dissociation between changes in ADHD symptoms and changes in measured driving measures. While data to date are limited on the ADHD-specific effects of pharmacotherapies used for ADHD on driving, it is clear from our review that these agents have effects on driving-relevant behaviors. Further research is urgently needed to develop an evidence base for clinically predictable effects of pharmacotherapy on driving safety in individuals with ADHD. If possible, clinicians should evaluate the positive and negative effects of pharmacotherapy on driving in their clients.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to prepare this manuscript.

Conflict of interest

Craig Surman, MD, reports the following conflicts in his lifetime. Speaking/education: Arbor, McNeil, Janssen, Janssen-Ortho, Novartis, Shire, and Reed/MGH Academy. Global medical education: funded by multiple companies. Research Support: MGH Adult ADHD Program: National Institutes of Health, Abbot, Cephalon, Hilda and Preston Davis Foundation, Eli Lilly, Magceutics, J & J/McNeil, Merck, Magceutics/Neurocentria, Nordic Naturals, Nestle/Pamlab, Pfizer, Organon, Shire, Takeda. Consulting: McNeil, Nutricia/Dannone, Rhodes, Takeda, Shire, Somaxon. Book royalties: Fast Minds: How to Thrive if you have ADHD (Or Think you Might), ADHD in Adults: A Practical Guide to Evaluation and Management. Ronna Fried, EdD, Lauren Rhodewalt, and Heidi Boland have no conflicts of interest.

References

  1. 1.
    World Health Organization. World Health Statistics 2016. Road traffic injuries. Geneva: World Health Organization; 2016. http://www.who.int/gho/publications/world_health_statistics/2016/whs2016_annexa_roadtraffic.pdf?ua=1&ua=1. Accessed 16 Nov 2016
  2. 2.
    Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, Doyle AE. Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry. 2000;48(1):9–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Kessler RC. Prevalence of adult ADHD in the United States: results from the national comorbidity survey replication (NCS-R). Paper presented at: Annual Meeting of the American Psychiatric Association: New York; May 1–6, 2004.Google Scholar
  4. 4.
    Faraone SV. Adult ADHD: A family-genetic perspective. Paper presented at: 157th Annual Meeting of the American Psychiatric Association; New York; May 1–6, 2004.Google Scholar
  5. 5.
    Biederman J, Faraone SV, Mick E. Psychiatric and functional outcome of adolescent females with ADHD: a large, controlled, five-year longitudinal follow-up study. Paper presented at: 158th Annual meeting of the American Psychiatric Association: Atlanta; May 21–26, 2005.Google Scholar
  6. 6.
    Vaa T. ADHD and relative risk of accidents in road traffic: a meta-analysis. Accid Anal Prev. 2014;62:415–25.CrossRefPubMedGoogle Scholar
  7. 7.
    Chang Z, Lichtenstein P, D’Onofrio BM, Sjölander A, Larsson H. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication. JAMA Psychiatry. 2014;71:319.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jerome L, Segal A, Habinski L. What we know about ADHD and driving risk: a literature review, meta-analysis and critique. J Can Acad Child Adolesc Psychiatry. 2006;15(3):105–25.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Barkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin N Am. 2004;27:233–60.CrossRefGoogle Scholar
  10. 10.
    Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics. 1996;98(6 Pt 1):1089–95.PubMedGoogle Scholar
  11. 11.
    Cox DJ, Merkel RL, Kovatchev B, Seward R. Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder. J Nerv Ment Dis. 2000;188:230–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Fischer M, Barkley RA, Smallish L, Fletcher K. Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid Anal Prev. 2007;39:94–105.CrossRefPubMedGoogle Scholar
  13. 13.
    Surman CB, Hammerness PG, Pion K, Faraone SV. Do stimulants improve functioning in adults with ADHD? A review of the literature. Eur Neuropsychopharmacol. 2013;23(6):528–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Tzepacz PT, Williams DW, Kelsey D. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6 month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Chang Z, Quinn PD, Hur K. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA. 2017;74(6):597–603.Google Scholar
  16. 16.
    Gobbo MA, Louzã MR. Influence of stimulant and non-stimulant drug treatment on driving performance in patients with attention deficit hyperactivity disorder: A systematic review. Eur Neuropsychopharmacol. 2014;24:1425–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Cox DJ, Merkel RL, Penberthy JK, Kovatchev B, Hankin CS. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. J Am Acad Child Adolesc Psychiatry. 2004;43:269–75.CrossRefPubMedGoogle Scholar
  18. 18.
    Cox DJ, Mikami AY, Cox BS, Coleman MT, Mahmood A, Sood A, et al. Effect of long-acting OROS methylphenidate on routine driving in young adults with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2008;162:793.CrossRefPubMedGoogle Scholar
  19. 19.
    Cox DJ, Davis M, Mikami AY, Singh H, Merkel RL, Burket R. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2012;32:225–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Verster JC, Bekker EM, Roos MD, Minova A, Eijken EJ, Kooij JS, et al. Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial. J Psychopharmacol. 2008;22:230–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Sobanski E, Sabljic D, Alm B, Dittmann R, Wehmeier P, Skopp G, et al. Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine. Eur Psychiatry. 2013;28:379–85.CrossRefPubMedGoogle Scholar
  22. 22.
    Cox DJ, Humphrey JW, Merkel RL, Penberthy JK, Kovatchev B. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Med. 2004;17:235–9.CrossRefGoogle Scholar
  23. 23.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006;118:e704–10.CrossRefPubMedGoogle Scholar
  24. 24.
    Bjørkli CA, Flø M, Jenssen GD, Ryum T, Zeiner P. Assessment of fitness to drive among patients with learning difficulties. SINTEF. 2005;STF50:A05027.Google Scholar
  25. 25.
    Barkley RA, Murphy KR, O’connell T, Connor DF. Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder. J Saf Res. 2005;36:121–31.CrossRefGoogle Scholar
  26. 26.
    Kay GG, Michaels MA, Pakull B. Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine. J Atten Disord. 2009;12:316–29.CrossRefPubMedGoogle Scholar
  27. 27.
    Biederman J, Fried R, Hammerness P, Surman C, Mehler B, Petty CR, et al. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: A randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J Psychiatr Res. 2012;46:484–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Barkley RA, Anderson DL, Kruesi M. A pilot study of the effects of atomoxetine on driving performance in adults with ADHD. J Atten Disord. 2007;10:306–16.CrossRefPubMedGoogle Scholar
  29. 29.
    Reimer B, D’Ambrosio LA, Gilbert J, Coughlin JF, Biederman J, Surman C, et al. Behavior differences in drivers with attention deficit hyperactivity disorder: the driving behavior questionnaire. Accid Anal Prev. 2005;37:996–1004.CrossRefPubMedGoogle Scholar
  30. 30.
    Biederman J, Fried R, Hammerness P, Surman C, Mehler B, Petty CR, et al. The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the manchester driving behavior questionnaire. J Adolesc Health. 2012;51:601–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Barkley RA, Murphy KR, Dupaul GJ, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002;8.Google Scholar
  32. 32.
    Barkley RA, Cox D. A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Saf Res. 2007;38:113–28.CrossRefGoogle Scholar
  33. 33.
    Lew HL, Poole JH, Lee EH, Jaffe DL, Huang H-C, Brodd E. Predictive validity of driving-simulator assessments following traumatic brain injury: a preliminary study. Brain Inj. 2005;19:177–88.CrossRefPubMedGoogle Scholar
  34. 34.
    Lundqvist A, Gerdle B, Rönnberg J. Neuropsychological aspects of driving after a stroke in the simulator and on the road. Appl Cogn Psychol. 2000;14:135–50.CrossRefGoogle Scholar
  35. 35.
    Rizzo M, Kellison IL. The Brain on the Road. In: Marcotte TD, Grant I, editors. Neuropsychology of everyday functioning (the science and practice of neuropsychology). New York: Guilford Press; 2009. p. 168–208.Google Scholar
  36. 36.
    Cox DJ, Moore M, Burket R, Merkel RL, Mikami AY, Kovatchev B. Rebound effects with long-acting amphetamine or methylphenidate stimulant medication preparations among adolescent male drivers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18:1–10.CrossRefPubMedGoogle Scholar
  37. 37.
    Mikami AY, Cox DJ, Davis MT, Wilson HK, Merkel RL, Burket R. Sex differences in effectiveness of extended-release stimulant medication among adolescents with attention-deficit/hyperactivity disorder. J Clin Psychol Med Settings. 2009;16:233–42.CrossRefPubMedGoogle Scholar
  38. 38.
    Biederman J, Fried R, Monuteaux MC, Reimer B, Coughlin JF, Surman CB, Aleardi M, Dougherty M, Schoenfeld S, Spencer TJ, Faraone SV. A laboratory driving simulation for assessment of driving behavior in adults with ADHD: a controlled study. Ann Gen Psychiatry. 2007;6:4. doi: 10.1186/1744-859X-6-4.

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Craig B. H. Surman
    • 1
    • 2
  • Ronna Fried
    • 3
  • Lauren Rhodewalt
    • 4
  • Heidi Boland
    • 4
  1. 1.Harvard Medical SchoolBostonUSA
  2. 2.Adult ADHD Research ProgramMassachusetts General HospitalBostonUSA
  3. 3.Clinical and Research Programs for Pediatric PsychopharmacologyMassachusetts General HospitalBostonUSA
  4. 4.Pediatric PsychopharmacologyMassachusetts General HospitalBostonUSA

Personalised recommendations